Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of delandistrogene moxeparvovec (SRP-9001) in Duchenne muscular dystrophy completed, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-23